Search

Now showing items 1-4 of 4

The potential of new tumor endothelium-specific markers for the development of antivascular therapy.

Li, J-L; Harris, AL (2007-06)

Angiogenesis is a hallmark of solid tumors, and disruption of tumor vasculature is an active anticancer therapy in some cases. Several proteins expressed on the surface of tumor endothelium have been identified during the ...

Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.

Li, J-L; Sainson, RCA; Shi, W; Leek, R; Harrington, LS; Preusser, M; Biswas, S; Turley, H; Heikamp, E; Hainfellner, JA; Harris, AL (2007-12-01)

The vascular endothelial growth factor (VEGF) plays a key role in tumor angiogenesis. However, clinical trials targeting the VEGF pathway are often ineffective, suggesting that other factors/pathways are also important in ...

Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

Raval, RR; Lau, KW; Tran, MGB; Sowter, HM; Mandriota, SJ; Li, J-L; Pugh, CW; Maxwell, PH; Harris, AL; Ratcliffe, PJ (2005-07)

Defective function of the von Hippel-Lindau (VHL) tumor suppressor ablates proteolytic regulation of hypoxia-inducible factor alpha subunits (HIF-1alpha and HIF-2alpha), leading to constitutive activation of hypoxia pathways ...

Role of hypoxia-inducible factors in epigenetic regulation via histone demethylases.

Yang, J; Ledaki, I; Turley, H; Gatter, KC; Montero, J-CM; Li, J-L; Harris, AL (2009-10)

Eukaryotic chromatin is subject to multiple posttranslational histone modifications such as acetylation, methylation, phosphorylation, and ubiquitination. These various covalent modifications have been proposed to constitute ...